Wuhan Hiteck Biological Pharma Co Ltd (300683) - Total Assets
Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) holds total assets worth CN¥2.64 Billion CNY (≈ $385.87 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 300683 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Wuhan Hiteck Biological Pharma Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Wuhan Hiteck Biological Pharma Co Ltd (300683) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Wuhan Hiteck Biological Pharma Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Wuhan Hiteck Biological Pharma Co Ltd's total assets of CN¥2.64 Billion consist of 44.5% current assets and 55.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.3% |
| Accounts Receivable | CN¥307.61 Million | 10.5% |
| Inventory | CN¥108.98 Million | 3.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥279.24 Million | 9.5% |
| Goodwill | CN¥263.59 Million | 9.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300683 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wuhan Hiteck Biological Pharma Co Ltd's current assets represent 44.5% of total assets in 2024, a decrease from 82.5% in 2013.
- Cash Position: Cash and equivalents constituted 14.3% of total assets in 2024, down from 39.7% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 4.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 10.5% of total assets.
Wuhan Hiteck Biological Pharma Co Ltd Competitors by Total Assets
Key competitors of Wuhan Hiteck Biological Pharma Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Wuhan Hiteck Biological Pharma Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.60 | 4.03 | 3.62 |
| Quick Ratio | 4.25 | 3.66 | 3.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥883.24 Million | CN¥993.17 Million | CN¥960.99 Million |
Wuhan Hiteck Biological Pharma Co Ltd - Advanced Valuation Insights
This section examines the relationship between Wuhan Hiteck Biological Pharma Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.87 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -1.2% |
| Total Assets | CN¥2.94 Billion |
| Market Capitalization | $463.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wuhan Hiteck Biological Pharma Co Ltd's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Wuhan Hiteck Biological Pharma Co Ltd's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
The table below shows the annual total assets of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.94 Billion ≈ $429.72 Million |
-1.17% |
| 2023-12-31 | CN¥2.97 Billion ≈ $434.79 Million |
+9.79% |
| 2022-12-31 | CN¥2.71 Billion ≈ $396.03 Million |
+0.33% |
| 2021-12-31 | CN¥2.70 Billion ≈ $394.73 Million |
+23.37% |
| 2020-12-31 | CN¥2.19 Billion ≈ $319.96 Million |
+0.79% |
| 2019-12-31 | CN¥2.17 Billion ≈ $317.47 Million |
+0.66% |
| 2018-12-31 | CN¥2.16 Billion ≈ $315.40 Million |
+12.92% |
| 2017-12-31 | CN¥1.91 Billion ≈ $279.31 Million |
+83.67% |
| 2016-12-31 | CN¥1.04 Billion ≈ $152.07 Million |
+19.11% |
| 2015-12-31 | CN¥872.49 Million ≈ $127.67 Million |
+8.88% |
| 2014-12-31 | CN¥801.37 Million ≈ $117.27 Million |
+81.69% |
| 2013-12-31 | CN¥441.07 Million ≈ $64.54 Million |
-- |
About Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy fo… Read more